Liver MRI could spot dangerous drug interactions early

NCT ID NCT07541807

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special MRI scan can measure how two common drugs, metformin and ciclosporin, affect the liver. Twelve healthy volunteers received the MRI dye gadoxetate before and after taking the drugs. The goal was to see if the scan could detect changes in liver function, which could help identify risky drug interactions earlier in development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

gadoxetate (MRI dye), metformin, ciclosporin

What this could lead to

If successful, this could lead to a safer, non-invasive way to test how new drugs interact with the liver, reducing drug development failures.

What could go wrong

This is a very small, early-phase study in healthy volunteers, not patients. The MRI method may not prove reliable enough for widespread use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

  • University of Sheffield, POLARIS, 18 Claremont Crescent

    Sheffield, S10 2RX, United Kingdom